Stephen V Liu: Randomized phase II trial results on amrubicin vs cisplatin for SCLC

Stephen V Liu posted the following on X:

“Randomized phase II: 1L amrubicin + irinotecan vs cisplatin + irinotecan for SCLC (JMTO LC 08-01) in Clinical Lung Cancer (n=100). No significant difference.

For amrubicin: 1y OS 68%, mOS 14.8m, mPFS 4.8m, RR 70%.

For cisplatin: 1y OS 59%, mOS 13.5m, mPFS 5.4m, RR 55%.”

Randomized Phase II Trial of Amrubicin Plus Irinotecan Versus Cisplatin Plus Irinotecan in Chemo-naïve Patients with Extensive-Disease Small-Cell Lung

Authors: Hiroshige Yoshioka, Tadashi Ishida, Shinji Atagi, Akihiro Tamiya, Takashi Nishimura, Yasuo Iwamoto, Masashi Kanehara, Young Hak Kim, Yohei Korogi, Keisuke Tomii, Nobuyuki Katakami, Kiyoshi Komuta, Masanori Nishikawa, Akihiko Gemma, Kenichi Yamaki, Masaaki Kawahara, Chisato Miyakoshi, Tadashi Mio.

Source: Stephen V Liu/X

Stephen V Liu is an Associate Professor of Medicine at Georgetown University, where he holds the positions of Director of Thoracic Oncology and Head of Developmental Therapeutics at the Georgetown Lombardi Comprehensive Cancer Center. As a board-certified medical oncologist specializing in lung cancer and drug development, Dr. Liu is known for his expertise in advanced thoracic malignancies.

His research focuses on novel therapeutic agents and innovative combinations to improve treatment outcomes for patients with lung cancer. Dr. Liu has received multiple teaching awards and actively engages in post-graduate education initiatives. Furthermore, he co-hosts the official podcast of the International Association for the Study of Lung Cancer (IASLC), “Lung Cancer Considered”.